Institution
Children's Memorial Hospital
Healthcare•
About: Children's Memorial Hospital is a based out in . It is known for research contribution in the topics: Population & Transplantation. The organization has 5652 authors who have published 8967 publications receiving 283837 citations.
Topics: Population, Transplantation, Medicine, Poison control, Health care
Papers published on a yearly basis
Papers
More filters
McGill University1, Massachusetts Institute of Technology2, University of Minnesota3, Oregon Health & Science University4, French Institute of Health and Medical Research5, Necker-Enfants Malades Hospital6, University of Washington7, Stony Brook University8, Children's Memorial Hospital9, Harvard University10
TL;DR: Analysis of coding exons of the Wilms' tumor suppressor gene (WT1) for germline mutations provides evidence of a direct role for WT1 in Denys-Drash syndrome and thus urogenital system development.
876 citations
Boston Children's Hospital1, Children's Memorial Hospital2, Wake Forest University3, Oregon Health & Science University4, University of California, San Francisco5, University of British Columbia6, New York University7, Case Western Reserve University8, Mayo Clinic9, University of Pennsylvania10, Northwestern University11, Nottingham University Hospitals NHS Trust12, University of Alabama at Birmingham13, Rafael Advanced Defense Systems14, American Academy of Dermatology15, Seattle Children's16
TL;DR: This guideline addresses important clinical questions that arise in the management and care of AD, providing updated and expanded recommendations based on the available evidence.
Abstract: Atopic dermatitis (AD) is a chronic, pruritic, inflammatory dermatosis that affects up to 25% of children and 2% to 3% of adults. This guideline addresses important clinical questions that arise in the management and care of AD, providing updated and expanded recommendations based on the available evidence. In this first of 4 sections, methods for the diagnosis and monitoring of disease, outcomes measures for assessment, and common clinical associations that affect patients with AD are discussed. Known risk factors for the development of disease are also reviewed.
874 citations
TL;DR: This article presents a definitional framework of CMC that consists of substantial family-identified service needs, characteristic chronic and severe conditions, functional limitations, and high health care use and suggests a research agenda that uses a uniform definition.
Abstract: Children with medical complexity (CMC) have medical fragility and intensive care needs that are not easily met by existing health care models. CMC may have a congenital or acquired multisystem disease, a severe neurologic condition with marked functional impairment, and/or technology dependence for activities of daily living. Although these children are at risk of poor health and family outcomes, there are few well-characterized clinical initiatives and research efforts devoted to improving their care. In this article, we present a definitional framework of CMC that consists of substantial family-identified service needs, characteristic chronic and severe conditions, functional limitations, and high health care use. We explore the diversity of existing care models and apply the principles of the chronic care model to address the clinical needs of CMC. Finally, we suggest a research agenda that uses a uniform definition to accurately describe the population and to evaluate outcomes from the perspectives of the child, the family, and the broader health care system.
868 citations
Catholic University of the Sacred Heart1, Harvard University2, Columbia University3, Stanford University4, University of Western Ontario5, Washington University in St. Louis6, University of Texas Southwestern Medical Center7, University of Freiburg8, Children's Memorial Hospital9, University of California, Los Angeles10, University of Gothenburg11, Biogen Idec12, Nemours Foundation13
TL;DR: Among children with later‐onset SMA, those who received nusinersen had significant and clinically meaningful improvement in motor function as compared with those in the control group.
Abstract: Background Nusinersen is an antisense oligonucleotide drug that modulates pre–messenger RNA splicing of the survival motor neuron 2 (SMN2) gene. It has been developed for the treatment of spinal muscular atrophy (SMA). Methods We conducted a multicenter, double-blind, sham-controlled, phase 3 trial of nusinersen in 126 children with SMA who had symptom onset after 6 months of age. The children were randomly assigned, in a 2:1 ratio, to undergo intrathecal administration of nusinersen at a dose of 12 mg (nusinersen group) or a sham procedure (control group) on days 1, 29, 85, and 274. The primary end point was the least-squares mean change from baseline in the Hammersmith Functional Motor Scale–Expanded (HFMSE) score at 15 months of treatment; HFMSE scores range from 0 to 66, with higher scores indicating better motor function. Secondary end points included the percentage of children with a clinically meaningful increase from baseline in the HFMSE score (≥3 points), an outcome that indicates impro...
846 citations
Centers for Disease Control and Prevention1, Mario Negri Institute for Pharmacological Research2, University of Texas Health Science Center at Houston3, Northern Illinois University4, Children's Memorial Hospital5, Mayo Clinic6, Fudan University7, Columbia University8, Boston University9, RTI International10, University of Arizona11, University of Hawaii at Manoa12, University of Bari13, Wellcome Trust14, University College London15, University of California, San Francisco16, Mississippi University for Women17, University of Limoges18, UCL Institute of Neurology19, Medical University of South Carolina20, National Institutes of Health21, Karolinska Institutet22, University of Calgary23
TL;DR: The purpose of this document is to promote consistency in definitions and methods in an effort to enhance future population‐based epidemiologic studies, facilitate comparison between populations, and encourage the collection of data useful for the promotion of public health.
Abstract: Worldwide, about 65 million people are estimated to have epilepsy. Epidemiologic studies are necessary to define the full public health burden of epilepsy; to set public health and health care priorities; to provide information needed for prevention, early detection, and treatment; to identify education and service needs; and to promote effective health care and support programs for people with epilepsy. However, different definitions and epidemiologic methods complicate the tasks of these studies and their interpretations and comparisons. The purpose of this document is to promote consistency in definitions and methods in an effort to enhance future population-based epidemiologic studies, facilitate comparison between populations, and encourage the collection of data useful for the promotion of public health. We discuss: (1) conceptual and operational definitions of epilepsy, (2) data resources and recommended data elements, and (3) methods and analyses appropriate for epidemiologic studies or the surveillance of epilepsy. Variations in these are considered, taking into account differing resource availability and needs among countries and differing purposes among studies.
844 citations
Authors
Showing all 5672 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Jorge E. Cortes | 163 | 2784 | 124154 |
| Marc C. Hochberg | 127 | 691 | 87268 |
| Michael Andreeff | 117 | 959 | 54734 |
| Bharat Bhushan | 116 | 1276 | 62506 |
| Donald M. Lloyd-Jones | 115 | 706 | 112655 |
| David N. Herndon | 108 | 1227 | 54888 |
| Frederick J. Schoen | 102 | 434 | 42611 |
| Kathryn M. Edwards | 102 | 628 | 39467 |
| Alan R. Dyer | 95 | 283 | 44252 |
| Mark C. Willingham | 94 | 394 | 36167 |
| Nicholas Katsanis | 93 | 348 | 34133 |
| Peter D. Gluckman | 92 | 525 | 33375 |
| Helga Refsum | 90 | 316 | 37463 |
| Dale A. Schoeller | 90 | 391 | 30776 |
| Shlomo Shinnar | 90 | 288 | 25621 |